ERMA.ST Stock Analysis
ER
Uncovered
Enorama Pharma AB is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Enorama Pharma AB engages in the research, development and manufacture of pharmaceutical drug delivery system. The company is headquartered in Malmo, Skane. The company went IPO on 2016-06-10. The firm is mainly focused on the development of medical chewing gum that contains drugs. The firm's product Nicotine gum is a chewing gum contained drugs that help to overcome nicotine addiction. In addition, the medical chewing gum applications include pain management, allergy, cough and cold, among others. The firm distributes its products in Europe through pharmacy chains and grocery stores.